Member Info for stevej

I wondered more where he was really pushing the value of Receptor.AI , that he intended to acquire to add to the Sareum offer which would bring in monthly contracts cash. Maybe funded from SRA737 deal and then could make Sareum even more value for a licensing or buy out.

All just how my brain works and probably nothing too it but throwing it out there!

GLA

Potnak

I’m had similar thoughts and thought we might of got a RNS this morning and then CC tomorrow reflecting on the potential good news.

Tense is definitely the right word and be interesting to see if we get a CC today or tomorrow

GLA

Meant to add that the CC should be out Monday or Tuesday and looking forward to what topic he chooses?

Personally I also feel if a MOU is in play then we will hear something with the next 2-4 weeks which could mean MM games to obtain shares

GLA

Mayhem55

Good post and my thoughts also, just hoping buy out over a licensing deal but either should be very positive ?

GLA

From CC but surely we should get an update with more detail or are they saving for any NDA’s

Announced in August 2025, the partnership is focused on accelerating the discovery and optimisation of blood-brain barrier (BBB)-permeable, isoform-selective TYK2/JAK1 inhibitors for neuroinflammatory indications, including multiple sclerosis and Parkinson’s disease. The collaboration builds directly on our own preclinical work, where our proprietary Sareum Kinase Inhibitor Library platform identified three TYK2/JAK1 compounds with meaningful BBB penetration which is essential for CNS drug development. Receptor.AI brings to this work a tailored in silico programme, applying virtual screening, generative chemistry, and predictive modelling to identify targets with strong target binding, brain penetration, selectivity, and synthetic feasibility.

Progress within the collaboration has been steady. Following the initiation of lead optimisation work with Receptor.AI in August 2025, the initial rounds of AI-guided design, synthesis and in vitro assay have been completed with further assay work in progress. Sareum retains full ownership of all intellectual property and compounds arising from the collaboration, with no ongoing milestone payments due to Receptor.AI following conclusion of the project.

There is so much to Sareum and so many avenues for the next news, is tox next or something else first?

GLA

Celtic

Don’t forget the warrants and share options so probably just over £3

GLA

Colbalt,

Yes and deserved, but prefer HBD thoughts ( not impossible when you look at our portfolio 🤞

GLA

£500m + is realistic and fair for what we have without taking into phase 2 ourselves.

Remember many years ago (15 plus) that Tim wanted 50m at that time and vaguely remember seeing an article on it, so where we are now to me would mean Tim would want £500m+. The majority of share holders would to me be happy at this number, especially after buying some at 10p as one hell of a return 🤞

HBD

Personally I think they would do a deal where it’s sold over taking up front payments as we know it will be years before this could come to fruition and only John would likely still be below the retirement age and the rest into retirement and enjoying life. I suppose they could appoint new board directors and John and Tim could continue to be directors or indeed non execs but I really lean to selling as tidier for their needs in my opinion (my take and opinion only)

Look forward to us all being rewarded and appreciate all the opinions as non of us really know until it happens but think we all agree it won’t hopefully be long now

GLA

Hi HBD

Good post, I’m not too concerned on warrants if exercised on a good RNS but liked your take on last CC as you are spot on with your comment as always .

Hopefully get a new CC next week or early the week after would be preferred if a good RNS drops next week to help keep momentum. We have all waited long enough to genuinely be excited at where we currently are and the potential on multi fronts over the coming months.

Thanks once again

GLA

Interesting and not interspersed….. fat fingers on iPhone 🤣

DP64

Trader Matt thanks for your thoughts, mine are firstly we all live by our means and to potentially half your salary in return for a bonus would likely have an impact on their own monthly outgoings, I personally couldn’t do that and most people are probably the same.

Secondly, they have a good number of shares and share options so anything over £1 would make them very comfortable in their retirement.

Thirdly, just look at their ages as all close to retirement with JR being the youngest (59 I believe ) so to me a buy out would suit them and sooner rather than later as they will likely need to work for anyone acquiring them for a minimum of 6 months as part of any deal.

HNWI would worry me as the majority make their money by quickly turn around of their investments so likely be happy to take a quick doubling of their investment, which would be 40-50p

As TraderMatt rightly points out that it’s all about the tox results and how good we actually are, I’m confident here but still realistically feel this will be sold for around £1.50 to £3.00 per share purely due to the time it’s taken to get to where we are now and any suitor playing hard ball because of our cash flow. Hopefully wrong but would still be happy with £2-3 ( broker target is £1.74 from memory )now if I’m honest due to my low average and investment size.

All the above is just my personal opinion from being here 18 years, I fully believe in the science and our programs but the BOD are the weak link to me but SP just might be able to pull off and I’m hoping the silence is down to their strategy to maximize share value.

The next few months should be really interspersed and positive to me 🤞

GLA

DP64

Everyone is entitled to to their own opinion and whilst I appreciate you feel the Board are milking it, the majority disagree with your sentiment and your negativity towards the board without adding any real value is bound to get negative replies. The LTH are the first to admit they have made some poor decisions over the years, which is down to them being scientists over true business leaders and communication has been poor over the years, but to be fair to SP he is trying to improve this with the CC monthly posts and Desamax gave a very good reason for no RNS yet, which I fully agree could be the reason.

Sareum are in the best position currently than they have been in years and highly lightly in my opinion to show real value over the coming months and therefore reward its shareholders.

Maybe you are locked in at a high price and not been able to average down or haven’t wanted too but if you truly feel this won’t add value to your portfolio then you should sell up and take the loss ( if indeed it is a loss) as negativity and knocking the company isn’t going to help your investment if you are invested or maybe you are not and therefore just deramping which would upset other shareholders who have researched this share fully, add informative posts, and genuinely see the potential is near met now than over the last few years,

GLA

GLA

Surprised not to see a RNS this morning so sent an email reminding them they said they were looking forward to keeping shareholders updated holders updated and toxicity should have finished last week.

Will they reply or more importantly, will they acknowledge dosing has completed or first patients at least have finished if staggered via RNS

GLA, exciting times

Thanks PCS1954

Your first one was better than mine yesterday ( didn’t post it 😂), so team work 👏

I will be surprised if we don’t get a dosing complete RNS tomorrow, especially after halting the first trail but also beginning to think that maybe they don’t need to pacify shareholders at this time as they plan to give us very good news within the next week or two.

Just hope they understand positivity is going to help the share price and therefore any negotiations 🤞

GLA

Thanks PCS1954

I copied your data into AI and asked whether Sareum is likely to need the longer review and it suggests and if I’m reading right then they should know main headlines within 2-4 weeks from end of study

Just need a positive confirmation that dosing has finished and no issues encountered in the dosing

AI reply

Based on Sareum’s published Phase 1 data, SDC-1801 (often referred to as Sareum 1801) has a plasma half-life of approximately 17–20 hours in humans. This has been reported consistently by Sareum in multiple updates and was one of the reasons the company concluded that once-daily dosing is feasible.

If you’re considering what this means for a 16-week GLP toxicology study:

* A 17–20 hour half-life is not generally considered exceptionally long in toxicology.

* After dosing stops on Day 112, drug levels would typically decline substantially within about 5–7 half-lives (roughly 4–6 days).

* More than 95% of the drug would usually be eliminated after about 5 half-lives, and over 99% after about 7–10 half-lives, assuming linear kinetics.

Using an 18-hour half-life as an example:

Time after last dose Approximate drug remaining

18 hours 50%

36 hours 25%

72 hours 6.25%

5 days <1%

7 days Trace amounts

Therefore, for SDC-1801, a recovery period of 14–28 days would ordinarily be more than sufficient to assess reversibility of toxicological findings. An extended recovery period of 8–12 weeks would typically be reserved for biologics, compounds with very long half-lives, depot formulations, or situations where delayed toxicity is suspected. Based on the publicly available PK data, SDC-1801 does not appear to fall into that category.

One additional point: Sareum disclosed in 2025 that its previous 16-week GLP toxicology study was stopped because unexpected findings occurred more frequently in control animals than in SDC-1801-treated animals. The company later stated that the findings were considered unrelated to SDC-1801 and that the toxicology program was restarted.

So, if your question is whether SDC-1801’s half-life is long enough to require an unusually lengthy recovery phase after a 16-week tox study, the available evidence suggests no—its reported 17–20 hour half-life is relatively moderate for a once-daily oral small molecule.

Hi EP

It will take time to fully review the data, hence Q4 being mentioned for phase 2 ready status but my feelings is they will get an initial reports on how the study went and potentially feedback from the CRO vast experience.

I think it will be whether Sareum try to maximise the good news or issues out a standard reply to say complete but they did say they were looking forward to keeping us updated

Just my thoughts for what they are worth and everyone needs to make their own decisions on timings as we all are guessing from our own experiences

GLA

100%, we have seen a shortage of shares so getting out now could be very costly next week on news. Many of us have life changing number of shares and been here a while 😂, but believe! This is key in understanding its potential and just a fraction of our values would still be life changing for many. I honestly believe now is our time

GLA

Will we see an updated RNS Monday to say toxicity has concluded with no issues and hopefully that initial reports are extremely encouraging?

They said they would keep us updated, so fingers crossed.

Probably the best possible place to be in this Friday with multiple pending news, here’s to another blue day

GLA

Don’t forget sone warrants were pre consolidation so can’t be exercised until around £3.50 new money for 5 days, so happy to get these exercised 😊